Topical Cocaine Hydrochloride Composition for Stable Mucosal Anesthesia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing topical anesthetic compositions have stability issues and can cause systemic negative side effects, such as cardiovascular issues, and are not suitable for stable long-term storage or effective administration in mucous membranes.
Innovation Solution
A ready-to-use pharmaceutical composition comprising 4% cocaine hydrochloride and a preservative in an aqueous solution, with a pH of 2 to 4, which maintains cocaine hydrochloride concentration above 3.4% and stability under various temperature and humidity conditions, and is administered using absorbent articles for mucous membrane contact.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical anesthetic compositions are formulated for stability, then storage reliability is improved, but systemic absorption and negative side effects increase
Solution Approach 1:
A vasoconstrictor agent is introduced as an intermediary substance that mediates between the anesthetic and the bloodstream. The vasoconstrictor constricts blood vessels at the application site, creating a physical barrier that reduces systemic absorption of the anesthetic while allowing the anesthetic to maintain its local effect. This resolves the contradiction by adding a third component that protects against the harmful effect (systemic absorption) while preserving the useful effect (local anesthesia).
Solution Approach 2:
The pH of the composition is adjusted to a specific range (3.5-6.5) to optimize both stability and reduced systemic absorption. By changing the pH parameter, the composition achieves better storage stability while the controlled ionization state of the anesthetic at this pH reduces its systemic uptake. This parameter adjustment simultaneously addresses both concerns in the contradiction.
2Duration of action of stationary object
If topical anesthetic compositions are formulated for long-term storage, then duration of storage is improved, but manufacturing complexity increases
Solution Approach 1:
Multiple functional components (anesthetic, vasoconstrictor, buffering agents, preservatives) are merged into a single ready-to-use composition with a stabilized pH range. This combination approach allows the product to achieve long-term storage stability without requiring complex separate formulation steps or special manufacturing equipment. The merged composition can be manufactured using standard pharmaceutical processes, thus resolving the contradiction between extended storage duration and manufacturing simplicity.
3Quantity of substance
If higher concentration of anesthetic is used, then anesthetic effect is improved, but systemic absorption and side effects increase
Solution Approach 1:
The vasoconstrictor serves as an intermediary that allows higher anesthetic concentrations to be used safely. By constricting blood vessels, the vasoconstrictor creates a localized environment where high concentrations of anesthetic can be maintained at the application site without proportionally increasing systemic absorption. This enables achieving better anesthetic effect while the vasoconstrictor protects against systemic toxicity.
Solution Approach 2:
The composition creates a localized high concentration of anesthetic at the application site through the vasoconstrictor-mediated reduction in blood flow. This local quality enhancement allows potent anesthetic effect precisely where needed, while the reduced blood flow simultaneously limits the amount that can enter systemic circulation, thus resolving the contradiction between local efficacy and systemic safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves stable storage and effective local anesthesia with reduced systemic absorption, providing consistent anesthetic effects and minimizing side effects, suitable for diagnostic and surgical procedures on mucous membranes.
Implementation Method 1
A ready-to-use pharmaceutical composition comprising 4% cocaine hydrochloride and a preservative in an aqueous solution, with a pH of 2 to 4, which maintains cocaine hydrochloride concentration above 3.4% and stability under various temperature and humidity conditions
Implementation Method 2
The mechanism of action of both amides and esters are similar; each prevents conduction in nerve fibers by reversibly blocking sodium channels and preventing the transient rise in sodium conductance necessary for generation of an action potential. The primary mechanism of local anesthetics, in general, is to interfere with Na+ channel activity, thereby preventing depolarization of target cells and reducing or blocking nerve conduction.
Implementation Method 3
The vasoconstrictor reduces systemic absorption of the anesthetic and increases the anesthetic's local tissue retention time. Increased retention time allows the anesthetic to metabolize more slowly, until local vasoconstriction is reversed.
Data Source
AI summary
Novel pharmaceutical compositions including cocaine hydrochloride and methods of treating patients using those pharmaceutical compositions are described.